Details of Drug

Drug General Information (ID: D0849)
Drug Name		Iron protein succinylate
Drug Type		Small molecule
Drug Synonymous		DB11209; Iron protein succinylate Click to Show/Hide
Therapeutic Class		Iron Supplement

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM003 Affected organization distribution AM007 Pharmacodynamic antagonistic effects BM003 Complex formation BM005 Altered gastric pH BM009 Altered absorption (Unspecific) BM013 Competitive binding of plasma proteins BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Iron protein succinylate
Affected gastrointestinal absorption
	Complex formation					Drug Num: 35
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0515		Dolutegravir	C20H19F2N3O5	54726191	Major		Inter Info	[4]
D0181		Bictegravir	C21H18F3N3O5	90311989	Major		Inter Info	[5], [6], [7]
D0034		Alendronic acid	C4H13NO7P2	2088	Moderate		Inter Info	[8], [9], [10]
D0277		Cefdinir	C14H13N5O5S2	6915944	Moderate		Inter Info	[11], [12]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
D0433		Deferiprone	C7H9NO2	2972	Moderate		Inter Info	[48]
D0441		Demeclocycline	C21H21ClN2O8	54680690	Moderate		Inter Info	[49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]
D0530		Doxycycline	C22H24N2O8	54671203	Moderate		Inter Info	[49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]
D0561		Eltrombopag	C25H22N4O4	135449332	Moderate		Inter Info	[6], [70]
D0575		Entacapone	C14H15N3O5	5281081	Moderate		Inter Info	[71]
D0623		Etidronic acid	C2H8O7P2	3305	Moderate		Inter Info	[9], [72], [10]
D0712		Gatifloxacin	C19H22FN3O4	5379	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
D0716		Gemifloxacin	C18H20FN5O4	9571107	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
D0144		Baloxavir marboxil	C27H23F2N3O7S	124081896	Moderate		Inter Info	[78]
D0438		Delafloxacin	C18H12ClF3N4O4	487101	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
D1175		Omadacycline	C29H40N4O7	54697325	Moderate		Inter Info	[49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]
D1445		Sarecycline	C24H29N3O8	54681908	Moderate		Inter Info	[49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]
D0893		Lanthanum carbonate	C3La2O9	168924	Moderate		Inter Info	[80], [5], [6], [81], [57], [58]
D0918		Levodopa	C9H11NO4	6047	Moderate		Inter Info	[82], [50], [83], [84]
D0919		Levofloxacin	C18H20FN3O4	149096	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
D0925		Levothyroxine	C15H11I4NO4	5819	Moderate		Inter Info	[85]
D0934		Liothyronine	C15H12I3NO4	5920	Moderate		Inter Info	[85]
D0935		Liotrix	C30H21I7N2Na2O8	71371	Moderate		Inter Info	[85]
D1035		Methyldopa	C10H13NO4	38853	Moderate		Inter Info	[86], [87], [50]
D1070		Minocycline	C23H27N3O7	54675783	Moderate		Inter Info	[49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]
D1092		Moxifloxacin	C21H24FN3O4	152946	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
D1155		Norfloxacin	C16H18FN3O3	4539	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
D1165		Ofloxacin	C18H20FN3O4	4583	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
D1245		Penicillamine	C5H11NO2S	5852	Moderate		Inter Info	[88], [89], [90], [91], [92], [93], [94], [37]
D1369		Quinapril	C25H30N2O5	54892	Moderate		Inter Info	[6], [95]
D1412		Risedronic acid	C7H11NO7P2	5245	Moderate		Inter Info	[8], [9], [10]
D1564		Tetracycline	C22H24N2O8	54675776	Moderate		Inter Info	[49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]
D1577		Thyroid, porcine	NA	NA	Moderate		Inter Info	[85], [96], [97]
D1635		Triethylenetetramine	C6H18N4	5565	Moderate		Inter Info	[98]
D1657		Trovafloxacin	C20H15F3N4O3	62959	Moderate		Inter Info	[16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
	Altered gastric pH					Drug Num: 7
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0458		Dexlansoprazole	C16H14F3N3O2S	9578005	Moderate		Inter Info	[60], [61], [62], [63], [64], [65], [66], [67], [68], [69]
D0603		Esomeprazole	C17H19N3O3S	9568614	Moderate		Inter Info	[60], [61], [62], [63], [64], [65], [66], [67], [68], [69]
D0892		Lansoprazole	C16H14F3N3O2S	3883	Moderate		Inter Info	[60], [61], [62], [63], [64], [65], [66], [67], [68], [69]
D1179		Omeprazole	C17H19N3O3S	4594	Moderate		Inter Info	[60], [61], [62], [63], [64], [65], [66], [67], [68], [69]
D1222		Pantoprazole	C16H15F2N3O4S	4679	Moderate		Inter Info	[60], [61], [62], [63], [64], [65], [66], [67], [68], [69]
D1373		Rabeprazole	C18H21N3O3S	5029	Moderate		Inter Info	[60], [61], [62], [63], [64], [65], [66], [67], [68], [69]
D0337		Cimetidine	C10H16N6S	2756	Minor		Inter Info	[101], [102], [103], [104]
	Altered absorption (Unspecific)					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0647		Ferric carboxymaltose	C24H44FeO25-	86278165	Moderate		Inter Info	[73], [74], [75], [76], [77]
D0654		Ferumoxytol	Fe3H2O4	14789	Moderate		Inter Info	[73], [74], [75], [76], [77]
D0848		Iron Dextran	FeH2O4S	105075	Moderate		Inter Info	[73], [74], [75], [76], [77]
D0648		Ferric derisomaltose	C18H34FeO16+3	86278348	Moderate		Inter Info	[73], [74], [75], [76], [77]
D0850		Iron sucrose	C12H29Fe5Na2O23	91663255	Moderate		Inter Info	[73], [74], [75], [76], [77]
D1484		Sodium ferric gluconate complex	C6H11FeNaO7+3	23693558	Moderate		Inter Info	[73], [74], [75], [76], [77]
Affected organization distribution
	Competitive binding of plasma proteins					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0708		Gallium chloride Ga-67	Cl3Ga	73415785	Moderate		Inter Info	[79]
Pharmacodynamic antagonistic effects
	Attenuated pharmacological effects (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1776		Dimercaprol	C3H8OS2	3080	Major		Inter Info	[1], [2], [3]
D0313		Chloramphenicol	C11H12Cl2N2O5	5959	Moderate		Inter Info	[13], [14], [15]
D1703		Vitamin E	C29H50O2	14985	Moderate		Inter Info	[99], [100]

References
1	Desmedt S, Spinewine A, Jadoul M, Henrard S, Wouters D, Dalleur O. Impact of a clinical decision support system for drug dosage in patients with renal failure.?Int J Clin Pharm. 2018;40(5):1225-1233. [PMID: 29785684]
2	Chenoweth MB "Clinical uses of metal-binding drugs." Clin Pharmacol Ther 9 (1968): 365-87. [PMID: 4984845]
3	Product Information. BAL in Oil (dimercaprol). Becton Dickinson, Franklin Lakes, NJ.
4	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
5	Cerner Multum, Inc. "Australian Product Information.".
6	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
7	Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir). Gilead Sciences, Foster City, CA.
8	Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
9	Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
10	Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
11	Product Information. Omnicef (cefdinir). Parke-Davis, Morris Plains, NJ.
12	Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I "Impairment of cefdinir absorption by iron ion." Clin Pharmacol Ther 54 (1993): 473-5. [PMID: 8222489]
13	Saidi P, Wallerstein RO, Aggeler PM "Effect of chloramphenicol on erythropoiesis." J Lab Clin Med 57 (1961): 247-56
14	Haile CA "Chloramphenicol toxicity." South Med J 70 (1977): 479-80
15	Scott JL, Finegold SY, Belkin GA, Lawrence JS "A controlled double-blind study of the hematologic toxicity of chloramphenicol." N Engl J Med 272 (1965): 1137-42
16	Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
17	Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11. [PMID: 10567782]
18	Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6. [PMID: 1540482]
19	Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2. [PMID: 1503446]
20	Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3. [PMID: 2360833]
21	Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7. [PMID: 2751276]
22	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
23	Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58. [PMID: 9916608]
24	Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103. [PMID: 10671902]
25	Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82. [PMID: 7955811]
26	Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51. [PMID: 8192452]
27	Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71. [PMID: 10223915]
28	Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5. [PMID: 2598571]
29	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
30	Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9. [PMID: 3382110]
31	Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102. [PMID: 2712548]
32	Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4. [PMID: 2610494]
33	Product Information. Baxdela (delafloxacin). Melinta Therapeutics, Lincolnshire, IL.
34	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
35	Product Information. Levaquin (levofloxacin). Ortho Pharmaceutical Corporation, Raritan, NJ.
36	Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
37	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
38	Product Information. Trovan (trovafloxacin). Pfizer US Pharmaceuticals, New York, NY.
39	Product Information. Zagam (sparfloxacin). Rhone-Poulenc Rorer, Collegeville, PA.
40	Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4. [PMID: 8471407]
41	Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24. [PMID: 1329615]
42	Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6. [PMID: 8820479]
43	Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7. [PMID: 9222077]
44	Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60. [PMID: 1724637]
45	Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901. [PMID: 2754785]
46	Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72. [PMID: 9257738]
47	Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7. [PMID: 2610502]
48	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
49	Xu D, Xiao Y, Pan H, Mei Y. Toxic effects of tetracycline and its degradation products on freshwater green algae.?Ecotoxicol Environ Saf. 2019;174:43-47. [PMID: 30818259]
50	Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5. [PMID: 2054263]
51	Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11. [PMID: 5031537]
52	Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3. [PMID: 5559446]
53	Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54. [PMID: 946598]
54	Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4. [PMID: 5483323]
55	Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3. [PMID: 4607747]
56	Product Information. Minocin (minocycline). Lederle Laboratories, Wayne, NJ.
57	Product Information. Nuzyra (omadacycline). Paratek Pharmaceuticals, Inc., Boston, MA.
58	Product Information. Seysara (sarecycline). Allergan Inc, Irvine, CA.
59	Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80. [PMID: 729621]
60	Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
61	Nand S, Tanvetyanon T "Proton pump inhibitors and iron deficiency: is the connection real?" South Med J 97 (2004): 799. [PMID: 15455957]
62	Product Information. Aciphex (rabeprazole) Janssen Pharmaceuticals, Titusville, NJ.
63	Product Information. Kapidex (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
64	Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65	Product Information. Prevacid (lansoprazole). TAP Pharmaceuticals Inc, Deerfield, IL.
66	Product Information. Prilosec (omeprazole). Merck & Co, Inc, West Point, PA.
67	Product Information. Protonix (pantoprazole) Wyeth-Ayerst Laboratories, Philadelphia, PA.
68	Sharma VR, Brannon MA, Carloss EA "Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia." South Med J 97 (2004): 887-9. [PMID: 15455980]
69	Stewart CA, Termanini B, Sutliff VE, et al "Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy." Aliment Pharmacol Ther 12 (1998): 83-98. [PMID: 9692706]
70	Product Information. Promacta (eltrombopag). GlaxoSmithKline, Research Triangle Park, NC.
71	Product Information. Comtan (entacapone) Novartis Pharmaceuticals, East Hanover, NJ.
72	Product Information. Fosamax (alendronate). Merck &amp Co, Inc, West Point, PA.
73	Product Information. Accrufer (ferric maltol). Shield Therapeutics, Wilmington, DE.
74	Product Information. Feraheme (ferumoxytol). Alza Pharmaceuticals, Mountain View, CA.
75	Product Information. Ferrlecit (sodium ferric gluconate complex). sanofi-aventis, Bridgewater, NJ.
76	Product Information. INFeD (iron dextran). Schein Pharmaceuticals Inc, Florham Park, NJ.
77	Product Information. Venofer (iron sucrose) American Regent Laboratories Inc, Shirley, NY.
78	Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
79	Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga)). Bristol-Myers Squibb, Princeton, NJ.
80	Canadian Pharmacists Association.
81	Product Information. Fosrenol (lanthanum carbonate). Shire US Inc, Florence, KY.
82	Campbell NR, Hasinoff B "Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism." Clin Pharmacol Ther 45 (1989): 220-5. [PMID: 2920496]
83	Campbell NR, Rankine D, Goodridge AE, Hasinoff BB, Kara M "Sinemet-ferrous sulphate interaction in patients with Parkinson's disease." Br J Clin Pharmacol 30 (1990): 599-605. [PMID: 2291872]
84	Greene RJ, Hall AD, Hider RC "The interaction of orally administered iron with levodopa and methyldopa therapy." J Pharm Pharmacol 42 (1990): 502-4. [PMID: 1980293]
85	Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC "Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism." Ann Intern Med 117 (1992): 1010-3. [PMID: 1443969]
86	Campbell N, Paddock V, Sundaram R "Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate." Clin Pharmacol Ther 43 (1988): 381-6. [PMID: 3356082]
87	Campbell NR, Campbell RR, Hasinoff BB "Ferrous sulfate reduces methyldopa absorption: methyldopa: iron complex formation as a likely mechanism." Clin Invest Med 6 (1990): 329-32. [PMID: 2078911]
88	Haagsma CJ "Clinically important drug interactions with disease-modifying antirheumatic drugs." Drugs Aging 13 (1998): 281-9. [PMID: 9805209]
89	Harkness JA, Blake DR "Penicillamine nephropathy and iron." Lancet 2 (1982): 1368-9. [PMID: 6129465]
90	Joyce DA "D-penicillamine pharmacokinetics and pharmacodynamics in man." Pharmacol Ther 42 (1989): 405-27. [PMID: 2672052]
91	Lyle WH "Penicillamine and iron." Lancet 2 (1976): 420. [PMID: 73880]
92	Netter P, Bannwarth B, Pere P, Nicolas A "Clinical pharmacokinetics of D-penicillamine." Clin Pharmacokinet 13 (1987): 317-33. [PMID: 3319347]
93	Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG "Reduction in oral penicillamine absorption by food, antacid and ferrous sulfate." Clin Pharmacol Ther 33 (1983): 465-70. [PMID: 6831825]
94	Product Information. Cuprimine (penicillamine). Merck & Co, Inc, West Point, PA.
95	Multum Information Services, Inc. Expert Review Panel.
96	Product Information. Armour thyroid (thyroid desiccated). Forest Pharmaceuticals, St. Louis, MO.
97	Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
98	Product Information. Syprine (trientine). Aton Pharma, Lawrenceville, NJ.
99	Graeber JE, Williams ML, Oski FA "The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction." J Pediatr 90 (1977): 282-4
100	Melhorn DK, Gross S "Relationships between iron-dextran and vitamin E in iron deficiency anemia in children." J Lab Clin Med 74 (1969): 789-802
101	Bianchi FM, Cavassini GB, Leo P "Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists." Int J Clin Pharmacol Ther Toxicol 31 (1993): 209-17. [PMID: 8100220]
102	Partlow ES, Campbell NRC, Chan SC, Pap KM, Granberg K, Hasinoff BB "Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion." Clin Pharmacol Ther 59 (1996): 389-93. [PMID: 8612382]
103	Product Information. Tagamet (cimetidine). SmithKline Beecham, Philadelphia, PA.
104	Rosner F "Cimetidine and iron absorption." Lancet 1 (1978): 95.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence